Danaher Secures $5 Billion Credit Line to Support Commercial Paper Program
Danaher Corporation (NYSE: DHR) has secured a massive $5 billion revolving credit facility, according to an 8-K filing with the Securities and Exchange Commission on April 17, 2026. The 364-day facility, arranged with Bank of America as Administrative Agent, provides the life sciences and diagnostics giant with substantial financial flexibility as it continues to execute its growth strategy.
The Deal
The credit facility, which expires on April 15, 2027, represents one of the largest revolving credit arrangements in the healthcare technology sector this year. Bank of America, N.A. serves as Administrative Agent, leading a syndicate of lenders in the transaction.
The facility's structure offers Danaher significant flexibility with competitive pricing. Borrowings based on Term SOFR carry interest rates ranging from SOFR plus 58.5 to 108.5 basis points, depending on Danaher's long-term debt credit rating. Base Rate Loans feature even tighter spreads, with margins of 0 to 8.5 basis points above the base rate. Additionally, Danaher pays a modest 4.0 basis point annual facility fee on the total commitment, regardless of usage.
A notable feature of the agreement allows Danaher to convert any outstanding loans at maturity into term loans for an additional year, subject to a 0.50% fee. This provision provides an additional liquidity backstop should market conditions warrant extended financing.
Strategic Rationale
The primary purpose of this credit facility is to provide liquidity support for Danaher's U.S. dollar-denominated commercial paper program, a critical component of the company's working capital management strategy. Commercial paper programs allow large corporations to efficiently manage short-term funding needs at attractive rates, but require backup credit facilities to maintain their credit ratings and ensure market access.
For a company of Danaher's scale—with 2025 revenues exceeding $24 billion—maintaining robust liquidity is essential for operational flexibility. The facility provides ample headroom for working capital fluctuations, potential acquisitions, and other general corporate purposes. Danaher has built its reputation through disciplined capital allocation and strategic acquisitions, having completed over 30 acquisitions in the past decade.
The timing of this facility is particularly strategic. With the previous credit facility approaching maturity and continued uncertainty in global markets, securing a new $5 billion commitment demonstrates strong lender confidence in Danaher's creditworthiness and business model. The company's diversified portfolio across life sciences, diagnostics, and environmental solutions positions it well for continued growth.
The facility's covenant structure is notably borrower-friendly, requiring only that Danaher maintain a Consolidated Leverage Ratio of 0.65 to 1.00 or less—a threshold the company comfortably meets given its strong balance sheet and consistent cash flow generation. This light covenant package reflects Danaher's investment-grade credit profile and strong relationship with its banking syndicate.
What to Watch
Several aspects of this transaction merit attention from investors and market observers. First, the facility's size and pricing suggest strong banking sector confidence in Danaher's credit profile despite broader economic uncertainties. The competitive margins indicate robust lender appetite for exposure to high-quality healthcare technology credits.
The facility's structure as backup for commercial paper issuance signals Danaher's intention to maintain an active presence in short-term funding markets. Commercial paper markets can experience volatility during periods of financial stress, making backup facilities essential for maintaining continuous market access. The $5 billion size provides substantial coverage for potential commercial paper outstandings.
From a regulatory perspective, the transaction faces minimal hurdles as a straightforward corporate financing. The credit agreement includes standard provisions restricting certain corporate actions, including limitations on liens, asset sales, and mergers. However, these covenants contain numerous exceptions and qualifications typical for investment-grade borrowers, providing Danaher with operational flexibility.
The change of control provisions warrant attention in the context of potential future M&A activity. Any change of control at Danaher would constitute an event of default, potentially accelerating repayment obligations. While no transformative transactions appear imminent, this provision protects lenders while potentially complicating any future strategic combinations.
Looking ahead, this facility positions Danaher well for continued execution of its growth strategy. The company's Danaher Business System, focused on continuous improvement and operational excellence, has consistently delivered strong returns on invested capital. With this enhanced liquidity position, management maintains flexibility to pursue value-creating opportunities while supporting ongoing operations.
The transaction also reflects broader trends in corporate finance, where companies are securing committed credit facilities to ensure liquidity access amid evolving market conditions. For Danaher shareholders, this proactive refinancing eliminates near-term refinancing risk and provides confidence in the company's financial flexibility through early 2027.